Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Dec;104(12):794-800.
doi: 10.1097/SMJ.0b013e318236c23a.

Differences in national antiretroviral prescribing patterns between black and white patients with HIV/AIDS, 1996-2006

Christine U Oramasionwu  1 , Carolyn M Brown, Kenneth A Lawson, Laurajo Ryan, Jeff Skinner, Christopher R Frei
Affiliations

Differences in national antiretroviral prescribing patterns between black and white patients with HIV/AIDS, 1996-2006

Christine U Oramasionwu et al. South Med J. 2011 Dec.

Abstract

Objectives: The benefit of improved health outcomes for blacks receiving highly active antiretroviral therapy (HAART) lags behind that of whites. This project therefore sought to determine whether the reason for this discrepancy in health outcomes could be attributed to disparities in use of antiretroviral therapy between black and white patients with HIV.

Materials and methods: The 1996-2006 National Hospital Ambulatory Medical Care Surveys were used to identify hospital outpatient visits that documented antiretrovirals. Patients younger than 18 years, of nonblack or nonwhite race, and lacking documentation of antiretrovirals were excluded. A multivariable logistic regression model was constructed with race as the independent variable and use of HAART as the dependent variable.

Results: Approximately 3 million HIV/AIDS patient visits were evaluated. Blacks were less likely than whites to use HAART and protease inhibitors (odds ratio, 95% CI 0.81 [0.81-0.82] and 0.67 [0.67-0.68], respectively). More blacks than whites used non-nucleoside reverse transcriptase inhibitors (odds ratio, 95% CI 1.18 [1.17-1.18]). In 1996, the crude rates of HAART were relatively low for both black and white cohorts (5% vs 6%). The rise in HAART for blacks appeared to lag behind that of whites for several years, until 2002, when the proportion of blacks receiving HAART slightly exceeded the proportion of whites receiving HAART. In later years, the rates of HAART were similar for blacks and whites (81% vs 82% in 2006). Blacks appeared less likely than whites to use protease inhibitors and more likely than whites to use non-nucleoside reverse transcriptase inhibitors from 2000 to 2004.

Conclusions: Blacks experienced a lag in the use of antiretrovirals at the beginning of the study; this discrepancy dissipated in more recent years.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Composition of HAART regimens for black and white patients with HIV/AIDS.
Fig. 2
Fig. 2
Composition of non-HAART regimens for black and white patients with HIV/AIDS.
Fig. 3
Fig. 3
Trends in HAART for black and white patients with HIV/AIDS, 1996–2006.
Fig. 4
Fig. 4
Trends in protease inhibitors (PIs) for black and white patients with HIV/AIDS, 1996– 2006.
Fig. 5
Fig. 5
Trends in non-nucleoside reverse transcriptase inhibitor (NNRTIs) for black and white patients with HIV/AIDS, 1996–2006.
Fig. 6
Fig. 6
Adjusted predictors for use of HAART for black versus white patients with HIV/AIDS, 1996–2006.
See this image and copyright information in PMC

Comment in

References

    1. Palella FJ, Jr., Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27–34. - PubMed
    1. Palacio H, Kahn JG, Richards TA, Morin SF. Effect of race and/or ethnicity in use of antiretrovirals and prophylaxis for opportunistic infection: a review of the literature. Public Health Rep. 2002;117:233–251. discussion 231-232. - PMC - PubMed
    1. Oramasionwu CU, Skinner J, Ryan L, Frei CR. Disparities in antiretroviral prescribing for blacks and whites in the United States. J Natl Med Assoc. 2009;101:1140–1144. - PubMed
    1. Sambamoorthi U, Moynihan PJ, McSpiritt E, Crystal S. Use of protease inhibitors and non-nucleoside reverse transcriptase inhibitors among Medicaid beneficiaries with AIDS. Am J Public Health. 2001;91:1474–1481. - PMC - PubMed
    1. Levine RS, Briggs NC, Kilbourne BS, et al. Black-White mortality from HIV in the United States before and after introduction of highly active antiretroviral therapy in 1996. Am J Public Health. 2007;97:1884–1892. - PMC - PubMed

Publication types

MeSH terms